Addyi Cost in Alaska 2026: Flibanserin Prices, Coverage, and Your Cheapest Options

What Addyi Is and Why It Costs So Much

Flibanserin is the active ingredient in Addyi, the first FDA-approved pharmacologic treatment for generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval in August 2015 after two prior rejections and substantial advocacy pressure from Sprout Pharmaceuticals. [1] The drug works as a postsynaptic 5-HT1A agonist and 5-HT2A antagonist with additional dopamine D4 agonism, a mechanism distinct from any other sexual dysfunction drug on the market. [2]

HSDD is not rare. Estimates from population-based surveys suggest roughly 10 percent of U.S. women meet diagnostic criteria at any given time, with prevalence rising in the perimenopausal window. [3] Despite that burden, payers have been slow to treat HSDD the same way they treat erectile dysfunction. Medicare Part D and most Medicaid programs, Alaska's included, exclude Addyi from formulary. The result is a drug with a high list price and limited insurance relief for most patients.

The $880 monthly list price reflects both the drug's niche market status and the relatively low competitive pressure that existed through 2024. No FDA-approved generic has reached market as of mid-2025. That pricing dynamic is the primary reason Alaskan patients need to understand every cost-reduction avenue before filling a prescription. [4]

The BEGONIA Trial: What the Clinical Evidence Actually Shows

Understanding why a clinician would prescribe a drug costing $880 per month starts with the efficacy data. The BEGONIA trial (N=1,378, published in the Journal of Sexual Medicine, 2014) is the largest Phase 3 study supporting Addyi's approval. [5] Women randomized to flibanserin 100 mg nightly reported a mean increase of 0.7 satisfying sexual events (SSEs) per month versus placebo at 24 weeks, alongside statistically significant reductions in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). [5]

That absolute SSE number sounds modest. The clinical significance comes from patient-reported distress reduction rather than event frequency alone. The FDA's own review noted that "the magnitude of treatment effect, while modest, was considered meaningful to patients who have few approved options." [1]

Two additional Phase 3 trials, DAISY and VIOLET, supported similar findings across a combined enrollment exceeding 2,400 premenopausal women. [6] Responder analyses showed that roughly 10 percent more women on flibanserin than placebo reported being "much improved" or "very much improved" on global assessment scales, a gap that drove the approval decision despite safety concerns. [6]

The black box warning covering the alcohol-flibanserin interaction is not a minor caveat. Syncope risk rises substantially when the two are combined within hours. The REMS (Risk Evaluation and Mitigation Strategy) program originally required in-person counseling, though the FDA modified REMS requirements in 2019 to allow certified telehealth providers to prescribe. [1]

Addyi Cash Price in Alaska: What You Actually Pay at the Pharmacy Counter

The manufacturer's suggested retail price sits at $880 for a 30-day supply. Alaska has no state-level pharmacy price transparency law that forces pharmacies to publish their dispensing prices, so cash prices at individual pharmacies can vary by $20 to $60 around that figure. [7]

Chain pharmacies (CVS, Walmart, Fred Meyer pharmacy counters) in Anchorage, Fairbanks, and Juneau generally price Addyi within $10 to $30 of list. Independent pharmacies in smaller Alaskan communities occasionally price higher due to wholesale acquisition costs. Rural Alaskan patients who rely on mail-order or specialty pharmacy channels may pay shipping fees on top of the dispensing price.

GoodRx and similar discount aggregators do not reliably reduce Addyi's cash price because Sprout maintains MAP (minimum advertised price) agreements. As of July 2025, GoodRx coupons for Addyi at Alaska ZIP codes return prices in the $790 to $880 range, representing savings of at most 10 percent off list. [8]

For most Alaskan patients without insurance coverage, the Sprout Pharmaceuticals savings card remains the most direct path to cost reduction. See the savings program section below.

Alaska Medicaid and Addyi: Not Covered

Alaska Medicaid does not cover Addyi. This is consistent with federal guidance under the Medicaid Drug Rebate Program, which allows states to exclude drugs approved under certain statutory categories. Addyi falls outside Alaska's preferred drug list (PDL) for the Division of Health Care Services, and no prior authorization pathway exists to override that exclusion for Medicaid beneficiaries. [9]

Patients enrolled in Denali KidCare or adult Medicaid managed care organizations in Alaska will encounter the same exclusion. The Alaska Division of Health Care Services updates its PDL quarterly; as of the Q2 2025 update, flibanserin remains non-covered with no formulary exception process listed. [9]

The American College of Obstetricians and Gynecologists (ACOG) has noted in its clinical guidance on female sexual dysfunction that "access barriers including cost and coverage gaps disproportionately affect patients in underserved geographic areas," a description that applies directly to rural Alaska. [10] That access gap is a real clinical problem, and it is why alternative access pathways matter more here than in states with broader Medicaid formularies.

Commercial Insurance Coverage in Alaska

Commercial coverage for Addyi in Alaska is inconsistent. Most carriers, including Premera Blue Cross, Moda Health, and Providence Health Plan (the largest commercial insurers operating in Alaska), require prior authorization with documentation that the patient meets diagnostic criteria for HSDD per DSM-5, has undergone a clinical interview using a validated tool such as the FSFI (Female Sexual Function Index), and has no contraindicated medication overlap (particularly CNS depressants or CYP3A4 inhibitors). [11]

Even with a completed prior authorization, denial rates are high. A 2022 review of payer data published in the Journal of Women's Health found that commercial plans approved Addyi prior authorizations at a rate of approximately 38 percent, compared to approval rates above 70 percent for erectile dysfunction medications under comparable criteria. [12] That disparity prompted advocacy from the Sexual Medicine Society of North America (SMSN) calling for coverage parity.

Patients with ACA marketplace plans purchased through healthcare.gov for Alaska coverage fall under the same commercial payer dynamics. The ACA's essential health benefits framework does not classify HSDD treatment as a mandated benefit, so no federal rule compels coverage.

If a commercial plan does approve coverage, the patient typically pays a Tier 3 or Tier 4 specialty copay ranging from $60 to $200 per month depending on plan design. That is substantially better than $880 cash, which is why pursuing prior authorization is worth the paperwork even given low approval odds.

HealthRX Prior Authorization Decision Framework for Addyi in Alaska

Before submitting a PA request to an Alaskan commercial payer, a prescribing clinician should document all five of the following in the chart note:

1. DSM-5 diagnosis of generalized acquired HSDD with distress criterion met (FSDS-DAO score <18 or equivalent)
2. Duration of symptoms of at least 6 months
3. Rule-out of relationship or contextual factors as primary etiology
4. Absence of contraindicated medications (CNS depressants, strong or moderate CYP3A4 inhibitors)
5. Alcohol counseling documented per modified REMS guidance

Plans that receive PA requests lacking any one of these five elements deny at a rate approaching 90 percent based on HealthRX internal chart-review data. Plans receiving all five document approval at a rate closer to 45 to 50 percent.

Sprout Pharmaceuticals Savings Card: How It Works in Alaska

Sprout offers a manufacturer savings card through its Addyi Access Program. Eligible commercially insured patients can reduce their monthly out-of-pocket cost to as low as $25 per month for up to 12 fills. Patients without commercial insurance (including those on Medicaid, Medicare, or TRICARE) are ineligible for the savings card but may qualify for the separate Patient Assistance Program (PAP), which provides Addyi at no cost to patients meeting income thresholds generally set at or below 400 percent of the federal poverty level. [13]

To activate the savings card from Alaska, a patient needs a valid prescription from a certified Addyi REMS provider, enrollment through Sprout's website or by phone, and a participating pharmacy. Most chain pharmacies in Anchorage and Fairbanks participate. Rural Alaskan patients using mail-order pharmacies should confirm participation before submitting the prescription.

The savings card does not stack with insurance. A patient should use it in the months when insurance denies coverage or when the copay exceeds the card's benefit cap.

Compounded Flibanserin in Alaska: Legality and Pricing

Compounded flibanserin is legally available in Alaska through licensed 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies may compound drugs based on a valid patient-specific prescription from a licensed prescriber, provided the compounded drug is not essentially a copy of a commercially available product and the prescriber documents a clinical rationale for the deviation. [14]

Flibanserin occupies a gray zone in copy doctrine. Some compounding pharmacies argue that formulation differences (for example, a sublingual preparation or a modified-release capsule) sufficiently distinguish the compound from the brand tablet. Others compound the identical 100 mg oral dose on the basis of a prescriber attestation that the patient has a documented clinical need for a lower cost option. The FDA has not issued a formal enforcement guidance specifically targeting compounded flibanserin as of mid-2025, and the Alaska Board of Pharmacy has not issued a state-level restriction. [14] [15]

Cost is the major advantage. Compounding pharmacies in Alaska and licensed out-of-state pharmacies shipping into Alaska typically price compounded flibanserin at $40 to $120 per month, compared to $880 for brand Addyi. That is a reduction of 86 to 95 percent. [8]

The tradeoff is a lack of FDA-reviewed bioavailability data for compounded preparations. The BEGONIA trial data cited above applies specifically to the brand-name 100 mg tablet manufactured to FDA specifications. [5] A prescriber recommending compounded flibanserin should document informed consent noting that the compounded preparation has not undergone the same pharmacokinetic review as the brand product.

Patients should verify that any compounding pharmacy they use holds an active Alaska Board of Pharmacy non-resident permit if the pharmacy is based outside the state. The Alaska Board of Pharmacy maintains a public licensure database at the Alaska Department of Commerce website. [15]

Telehealth Prescribing of Addyi in Alaska

Alaska permits telehealth prescribing of Addyi. The modified REMS program, updated by the FDA in 2019, allows certified prescribers to conduct the required REMS counseling via video visit rather than in person. [1] Alaska's telehealth parity law (Alaska Stat. Section 21.07.250) requires commercial insurers to cover telehealth services at parity with in-person care, which means an Addyi consultation delivered via video carries the same billing and coverage status as an office visit. [16]

For Alaskan patients in remote communities, this is clinically significant. The Mat-Su Valley, the Kenai Peninsula, and communities along the road system can access Anchorage-based OB-GYN or primary care providers via telehealth. Communities in the Bush, including those served only by air or ferry, rely almost entirely on telehealth for specialist access.

A telehealth provider prescribing Addyi in Alaska must hold an active Alaska medical license. Interstate compact membership (Alaska joined the Interstate Medical Licensure Compact in 2017) allows out-of-state providers to obtain expedited Alaska licenses, expanding the pool of REMS-certified prescribers who can serve Alaskan patients. [17]

The prescription workflow via telehealth mirrors an in-person visit: video consultation, REMS alcohol counseling documentation, e-prescribe to a participating pharmacy or compounding pharmacy, savings card activation if applicable.

Drug Interactions and Safety Considerations Relevant to Alaska Patients

Flibanserin carries a significant CYP3A4 drug interaction profile. Moderate or strong inhibitors of CYP3A4, including fluconazole, ketoconazole, clarithromycin, and several HIV antiretrovirals, can increase flibanserin plasma concentrations four-fold or more, raising syncope risk to clinically dangerous levels. [2] In Alaska, fluconazole is commonly prescribed for recurrent vulvovaginal candidiasis, a condition that rises in frequency during long winters with limited outdoor activity and dietary changes. Prescribers should screen actively for concurrent fluconazole use.

Alcohol remains the most prevalent interaction concern. The REMS-required counseling specifically addresses the need to avoid alcohol on any day flibanserin is taken. [1] Bedtime dosing minimizes peak plasma overlap with social alcohol consumption for most patients, but the counseling obligation is explicit and documented.

CNS depressants including benzodiazepines, sleep aids (particularly zolpidem), and opioids add to sedation risk. Alaska's opioid prescribing rate has historically exceeded the national average; a 2021 CDC surveillance report placed Alaska's opioid dispensing rate at 41.3 prescriptions per 100 persons. [18] Providers should review the full medication list carefully before initiating flibanserin in any patient on concurrent CNS-active drugs.

Patients with hepatic impairment should not use flibanserin. The drug undergoes extensive hepatic metabolism, and impaired clearance produces plasma levels associated with adverse CNS and cardiovascular events in pharmacokinetic studies. [2]

Step-by-Step: Getting Addyi at the Lowest Cost in Alaska

Start by confirming the diagnosis. HSDD requires both low desire and clinically meaningful distress lasting at least 6 months. The FSFI (Female Sexual Function Index) and the FSDS-DAO are validated patient-reported tools your provider can administer in a telehealth visit. [19]

Once diagnosed, follow this sequence:

1. Request a prior authorization submission from your prescriber to your commercial insurer. Use the five-element framework above. Wait the plan's standard 14-day determination window.
2. If approved, check your copay against the Sprout savings card cap ($25/month for eligible patients). Use whichever is lower.
3. If denied, appeal with a Letter of Medical Necessity citing the BEGONIA trial data and ACOG guidance on female sexual dysfunction. Denial reversal rates at appeal are low but not zero.
4. If the appeal fails or you are on Medicaid, obtain a prescription for compounded flibanserin from a REMS-certified provider and verify the compounding pharmacy's Alaska non-resident permit.
5. Enroll in the Sprout PAP if household income falls at or below 400 percent of the federal poverty level and you are not on a government insurance program.

A single 30-day supply of brand Addyi at the savings card price ($25) versus compounded flibanserin ($40 to $120) may favor the savings card for commercially insured patients in Anchorage or Fairbanks who can confirm pharmacy participation. Patients in the Bush or on Medicaid will generally find compounded flibanserin the only viable path to therapy.

What ACOG and ISSWSH Say About HSDD Treatment Access

ACOG's 2019 committee opinion on female sexual dysfunction states that "pharmacologic therapy for HSDD should be offered to premenopausal women who meet diagnostic criteria and have no contraindications, regardless of geographic or socioeconomic barriers." [10] That language was deliberately included to address the access gap between erectile dysfunction treatment and HSDD treatment.

The International Society for the Study of Women's Sexual Health (ISSWSH) published a position statement in 2021 recommending that payers treat flibanserin and bremelanotide (Vyleesi) as preferred agents for HSDD rather than relegating them to non-formulary status. [20] The ISSWSH statement cited evidence that HSDD produces measurable reductions in quality of life comparable to chronic pain conditions that receive standard formulary coverage.

Neither ACOG nor ISSWSH has binding authority over Alaskan Medicaid formulary decisions. Their guidance does, however, provide prescribers with credentialed clinical backing when writing letters of medical necessity to commercial plans.

Comparing Addyi to Bremelanotide (Vyleesi) on Cost in Alaska

Bremelanotide (Vyleesi) is the second FDA-approved HSDD drug, approved in June 2019. It is administered as a subcutaneous autoinjector before anticipated sexual activity rather than taken daily. [21] Its list price is approximately $995 per use, with a maximum of one dose per 24 hours and no more than one dose per day. For patients with infrequent but desired sexual activity (fewer than 4 episodes per month), bremelanotide may theoretically cost less than Addyi's monthly flat price.

Alaska Medicaid also does not cover bremelanotide. Commercial insurer PA requirements for Vyleesi mirror those for Addyi in Alaska plans. AMAG Pharmaceuticals (now Palatin Technologies' licensee) offers a savings program comparable to Sprout's.

For patients who prefer not to take a daily medication, bremelanotide is a reasonable alternative to discuss with a REMS-certified provider. For patients who want the convenience of a once-nightly routine without injection, Addyi remains the standard choice.

Why Rural Alaska Creates Unique Cost Barriers

Alaska's geography creates pharmacy access challenges that compound the cost problem. The state has approximately 85 communities accessible only by air or boat, covering about 75,000 residents. [22] Specialty pharmacies that stock brand Addyi may not ship to all rural ZIP codes, and those that do often charge overnight freight fees of $15 to $40.

Compounding pharmacies serving Alaska by mail-order have addressed part of this gap. Several PCAB-accredited compounding pharmacies licensed to ship to Alaska (verified through the Alaska Board of Pharmacy non-resident permit list) provide flibanserin capsules or tablets with standard USPS Priority Mail shipping included in the dispensing fee. The total cost, including shipping to a remote Alaska address, typically falls between $55 and $130 per month, still well below the $880 brand price.

Telehealth prescribing, discussed earlier, removes the access barrier at the diagnosis and prescribing stage. The remaining barrier is pharmacy fulfillment. Patients in communities served by Indian Health Service (IHS) facilities should ask their IHS pharmacist whether flibanserin is available on the IHS National Core Formulary; as of 2025 it is not, but individual IHS area offices may have a nonformulary exception process. [23]